drugset
drugset / Trial / NCT04616196

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196 ↗

Phase 1/2 Completed 25 enrolled Nektar Therapeutics
NaSequentialOpen-labelTreatment

Summary

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).

Timeline

Start
2020-10-30
Primary completion
2023-03-30
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject NKTR-255 Protein / enzyme biologic — Intravenous
Background Cetuximab Monoclonal antibody — —

Indications

colorectal cancer head and neck squamous cell carcinoma